GSK plc with ticker (LON:GSK) now has a potential downside of -2.2% according to JP Morgan.
JP Morgan set a target price of 1,400 GBX for the company, which when compared to the GSK plc share price of 1,432 GBX at opening today (26/06/2023) indicates a potential downside of -2.2%. Trading has ranged between 1,281 (52 week low) and 2,281 (52 week high) with an average of 7,656,897 shares exchanging hands daily. The market capitalisation at the time of writing is £58,484,645,180.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. It has a global network of about 12 vaccine manufacturing sites.
GSK plc -2.2% potential downside indicated by JP Morgan
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Charlotte Edwards
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.
